FindTrial
Sign In

MM-398

DRUG4 trials

Sponsors

Merrimack Pharmaceuticals, Ipsen, Sumitomo Pharma America, Inc., GERCOR - Multidisciplinary Oncology Cooperative Group

Conditions

ER/PR Positive Breast CancerMetastatic Breast Cancer With Active Brain MetastasisMetastatic Pancreatic AdenocarcinomaMetastatic Pancreatic CancerSolid TumorsTriple Negative Breast CancerUnresectable Advanced Cancer

Phase 1

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
CompletedNCT01770353
IpsenER/PR Positive Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis, Solid Tumors +1
Start: 2012-11-30End: 2018-10-02Updated: 2019-11-27
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
CompletedNCT02231723
Sumitomo Pharma America, Inc.Metastatic Pancreatic Adenocarcinoma
Start: 2014-08-31End: 2020-06-30Updated: 2023-11-18
A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
CompletedNCT02640365
GERCOR - Multidisciplinary Oncology Cooperative GroupUnresectable Advanced Cancer
Start: 2015-11-18End: 2016-12-07Updated: 2017-01-31

Phase 3

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
CompletedNCT01494506
Merrimack PharmaceuticalsMetastatic Pancreatic Cancer
Start: 2011-11-30End: 2015-10-31Updated: 2016-06-17

Related Papers

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer
Radiology Imaging Cancer2023-02-017 citations
SYST-13 PHASE II STUDY OF THE COMBINATION OF LIPOSOMAL IRINOTECAN AND PEMBROLIZUMAB FOR TRIPLE-NEGATIVE BREAST CANCER (TNBC) WITH BRAIN METASTASES (BM)
Neuro-Oncology Advances2022-08-01
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
CPT Pharmacometrics & Systems Pharmacology2021-11-0911 citations
Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers
Clinical Pharmacology in Drug Development2021-06-095 citations
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
Breast Cancer Research and Treatment2020-11-1744 citations
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
2020-10-109 citations
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer
Pancreas2019-12-1930 citations
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
Cancer Science2019-12-0244 citations
TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM)
Neuro-Oncology Advances2019-08-011 citations
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Cancers2019-07-2829 citations
Abstract CT048: Phase I expansion study of irinotecan liposome injection (nal-IRI) in patients with metastatic breast cancer (mBC)
Cancer Research2019-07-011 citations
Abstract CT048: Phase I expansion study of irinotecan liposome injection (nal-IRI) in patients with metastatic breast cancer (mBC)
Clinical Trials2019-07-01
Pharmacokinetic (PK) characterization of irinotecan liposome injection in patients (pts) with metastatic breast cancer (mBC).
Journal of Clinical Oncology2019-05-20
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
2019-03-0421 citations
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
European Journal of Cancer2019-01-14298 citations
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
2018-11-1735 citations
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
Annals of Oncology2018-10-015 citations
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
Annals of Oncology2018-10-012 citations
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Annals of Oncology2018-10-011 citations
CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress
Annals of Oncology2018-06-013 citations

27 more papers not shown